About Aspen Neuroscience
Developing autologous iPSC-derived cell replacement therapies for Parkinson’s disease and other CNS disorders
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- La Jolla, CA
- Founded
- 2018
- Company type
- Privately Held
- Company profile name
- Aspen Neuroscience, Inc.
Aspen Neuroscience is a clinical-stage regenerative medicine biotechnology company developing autologous induced pluripotent stem cell (iPSC)-derived therapies, beginning with Parkinson’s disease (PD). Our lead investigational therapy, sasineprocel (ANPD001), is designed to replace lost dopaminergic neurons and reconstruct the underlying neural circuitry to restore function and potentially slow disease progression - without the need for immunosuppression.
At Aspen, our team is passionate about bringing our world class science and manufacturing to patients. We aim to transform the lives of people living with PD with our personalized regenerative therapies that offer real hope where none existed before.
Specialties
- Stem Cells
- Induced Pluripotent Stem Cells
- Genomics
- Cell Therapy
- Parkinson's Disease
- Neuroscience
- Regenerative Medicine
- IPSCs
- bioinformatics
- biotech
- San Diego
- machine learning
- and autologous
Company locations
La Jolla, CA 92037, US
Locations listed on the company profile. These may include offices outside Canada, and not every location is hiring.
Business areas
- Biotechnology
- Life Science
- Medical
- Neuroscience
- Pharmaceutical
- Therapeutics
On LinkedIn
- Followers
- 13,067
- People linked to this company
- 134
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
387,000,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.